The Nuclear Medicine Software System segmentation by application distinguishes four primary use cases that collectively drive market revenue. Diagnostic Imaging platforms, which acquire, reconstruct, and display gamma camera and PET/SPECT data, represent the largest share, accounting for roughly 45 % of total sales due to widespread adoption in hospitals and imaging centers. Therapy Planning solutions, encompassing dose calculation and treatment simulation for radionuclide therapies, contribute about 25 % of the market, reflecting growing clinical interest in personalized theranostics. Research & Development tools, used for pre‑clinical studies, radiopharmaceutical design, and quantitative analysis, occupy an estimated 15 % of revenue, supported by academic and biotech investment. Finally, Clinical Workflow Management software that integrates scheduling, reporting, and regulatory compliance captures the remaining 15 %, as institutions seek end‑to‑end digitalization. These application categories are directly reflected in the accompanying pie‑chart, which quantifies their relative weight within the overall Nuclear Medicine Software System market.